We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Amryt Pharma Plc | LSE:AMYT | London | Ordinary Share | GB00BKLTQ412 | ORD 6P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 143.00 | 151.00 | 170.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
18/9/2020 14:39 | Things are looking up on Nasdaq. Just ONE solitary ADS traded so far today @ US$12.97. 🤣 | papillon | |
18/9/2020 12:37 | Yes, many, many, thanks for that AP103 trial information, diamondstar. If I might pick your brains, you state: "Amryt’s AP-103 is unique in that it is a polymer based, non-viral vector gene therapy - which is applied to the patients skin directly and will require repeat application." Is that not the case with Krystal Biotech's KB 103 viral based gene therapy? | papillon | |
18/9/2020 12:25 | Diamondstar thank you for your post. I thought that was the case, but confirmation is most helpful. We may not have to wait to long for some results. | sidam | |
18/9/2020 12:19 | Biotech FAB currently up over 120% on today's RNS. It contains the magic phrase, treatment for COVID 19. 😂 You can't go far wrong with an RNS containing a reference to COVID 19 treatment. It's the new Abracadabra! If only AMYT could get the magic phrase, treatment for COVID 19, into their RNS's!😢 | papillon | |
18/9/2020 02:03 | Regarding gene therapy trials in EB, these tend to be small studies, due to the highly targeted therapy and the large anticipated treatment effect. The Phase 2 studies for gene therapy products are typically small (e.g. 6-10 patients) and even the pivotal Ph 3 trials are usually small. For example, Krystal Biotech recently started their pivotal Ph 3 trial (GEM-3) with KB-103 in severe dystrophic EB, and this study aims to recruit 30 EB patients (compared to >200 in EASE Ph 3). Amryt’s AP-103 is unique in that it is a polymer based, non-viral vector gene therapy - which is applied to the patients skin directly and will require repeat application. | diamondstar1 | |
18/9/2020 01:45 | Looks Paps like it may have closed @ 12.72 on Nasdaq = 195.00p | diamondstar1 | |
17/9/2020 20:53 | Today, about 15 minutes before the close, I bought back 1000 of the 1500 shares I recently sold. Paid 210p per share. Back to 6000 shares. I'm sticking with those and await the next update on AP101, promised within weeks in the results RNS dated 9th September. With the benefit of hindsight probably not a good idea because still no interest being shown on Nasdaq. | papillon | |
16/9/2020 22:34 | Closed @ US$13 on Nasdaq. At the current exchange rate of 1.2968 that's equal to 200.5p per AMYT share on AIM. BLOODY Nasdaq!! In fairness to Nasdaq and American PI's the share price did rise significantly on AIM in anticipation of the Nasdaq listing so perhaps today's closing price on Nasdaq is a fair reflection of Amryt's current value. In retrospect the AMYT share price on AIM immediately prior to the Nasdaq listing was significantly overbought and far too high! I think we'll have to await further news on the AP101 front, primarily the official verdict on the efficacy of the treatment, as highlighted by diamondstar, or an acquisition as mentioned by Alphabravo321, before we see further progress in the AMYT share price Hope I'm wrong as I'm still holding 5000 shares. ATB PAPILLON | ultrasharp | |
16/9/2020 15:32 | Bermudashorts and diamondstar are the knowledgeable posters on this and the lse bb's, sidam and they might know. I doubt if anyone else does. PS. Lack of interest in AMYT continues today on Nasdaq (less than 10 trades so far and the largest is only for 300) so I haven't topped up today. ATB PAPILLON | ultrasharp | |
16/9/2020 15:20 | Does anyone have information on AP103 trials. My recollection is that management consider that as a gene therapy it will not require a large number patients and the results could be realised relatively quickly. Anyone know, if that is correct. I am aware it will not be a cure but a treatment that will have to be repeated on a regular basis if it obtains approval. | sidam | |
16/9/2020 12:51 | Some big buys gone through today. 60k just be reported from yesterday afternoon @ 213p when the spread was 206 - 214 so that was presumably a buy. Around the same time yesterday, but reported yesterday was a 100k trade @ 212.25p when the spread was the same. I think I might buy back some of those shares I sold yesterday. Probably worth waiting to see what Nasdaq opens at. | papillon | |
16/9/2020 12:35 | That’s the big question!! | bazworth | |
16/9/2020 12:16 | ???????????????????? | papillon | |
16/9/2020 09:07 | My bad ultra slob. | volsung | |
15/9/2020 17:27 | Is that who you reckon Cawkwell is, volsung? I very much doubt it as going by their photos one is a very fat slob (Cawkwell), whilst the other is a skinny slob (Winnifroth)! 😁 ATB PAPILLON | ultrasharp | |
15/9/2020 17:22 | That’ll be a first for me. Invested in something along with TW lol | volsung | |
15/9/2020 17:20 | Yes, you are right diamondstar. I thought the ADS's would kick on after that massive trade especially as the quote was momentarily 13.80 after, but reality has returned and its back down to 13.09 for a 589 trade. Presumably a sell so Nasdaq is back below the AIM price as per usual. Regarding Cawkwell, 40plus, he's definitely not infallible with his trades. He always seems to me to get as many trades wrong as he gets right these days. ATB PAPILLON | ultrasharp | |
15/9/2020 17:00 | Nice to see infamous short tack Simon Cawkwell (Aka Evil Knievil) had positive things to say about Amryt yesterday:- Today he posted he'd bought more shares at 2.20 | 40plus | |
15/9/2020 16:55 | That deal was transacted at 13.42? Still converts to £2.06. Paps - you managed to obtain a far better price on AIM this morning! | diamondstar1 | |
15/9/2020 16:42 | There was a massive 250k trade on Nasdaq around 25 minutes ago. Must have been a buy. That's 1.25m AMYT shares. I could have sold too soon this morning. Sods law! ATB PAPILLON | ultrasharp | |
15/9/2020 16:41 | There could be life in Nasdaq yet! | alphabravo321 | |
15/9/2020 14:51 | Opened down @ 12.47 on Nasdaq. 5 tiny trades so far all @ 12.47. The biggest is for 78 ADS's. A couple for just 1 ADS and another 2 for just 4 ADS's. What the hell is behind those trades? Some think that a single share trade on AIM is an MM signal, but I'm not wholly convinced of that! Listing on Nasdaq has been a disaster for the AMYT share price on AIM. I had great hopes in the run up to the listing on Nasdaq, but my hopes have been dashed. For whatever reason there seems to be no enthusiasm for Amryt on Nasdaq, despite the lofty analyst share price target prices. Yet Krystal Bloody Biotech (KRYS)appears to be a Nasdaq darling and has raised loads of cash without trashing it's share price | papillon | |
15/9/2020 11:04 | Understand that, but what trades cause the correlation? Unless of course it’s the ‘big boys’ at play! | bazworth | |
15/9/2020 10:42 | Bazworth - there is usually a high correlation if a stock is dual listed on different exchanges. If there is a significant difference, then this creates a potential arbitrage opportunity. | diamondstar1 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions